DBV Technologies to Present Preclinical Data on its Viaskin(R) Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting
November 18, 2015 01:35 ET
|
DBV Technologies
BAGNEUX, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies : IND Acceptance from FDA for a proof-of-concept trial using Viaskin(r) Milk in Milk-Induced Eosinophilic Esophagitis in Children
July 08, 2015 01:37 ET
|
DBV Technologies
BAGNEUX, France, July 8, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin(R) Milk in Pediatric Cow's Milk Allergy
June 30, 2015 01:39 ET
|
DBV Technologies
DSMB expressed no safety concerns and recommended that the study continue as planned
Initiation of Part B expected in the second half of 2015 pending consultation with regulatory...
DBV Technologies Confirms Planned Initiation of Viaskin(R) Peanut Global Phase III Clinical Trial in Children Following End-of-Phase II Meeting with FDA and PIP approval by EMA
June 22, 2015 18:22 ET
|
DBV Technologies
Phase III clinical trial in children expected to begin in Q4 2015
Comprehensive development plan for Viaskin Peanut announced
Bagneux, France, June 22, 2015 (GLOBE NEWSWIRE) -- DBV Technologies...
DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
June 04, 2015 01:38 ET
|
DBV Technologies
BAGNEUX, France, June 4, 2015 (GLOBE NEWSWIRE) -- DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the...
DBV Technologies: Mixed General Assembly of June 23, 2015
June 02, 2015 13:36 ET
|
DBV Technologies
BAGNEUX, France, June 2, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), French biopharmaceutical company, announces that it will hold its Mixed General...
DBV Technologies Reports Full Year 2014 Financial Results
March 25, 2015 02:37 ET
|
DBV Technologies
BAGNEUX, France, March 25, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced...
Viaskin(r) Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies
February 24, 2015 01:41 ET
|
DBV Technologies
VIPES Phase IIb data supports Viaskin® Peanut safety and efficacy in the treatment of peanut allergy
Preclinical data highlighted the unique and long-lasting therapeutic profile of...
Global offering of DBV Technologies ordinary shares
October 23, 2014 02:35 ET
|
DBV Technologies
BAGNEUX, France, Oct. 23, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), a clinical-stage specialty biopharmaceutical company announced today that the underwriters in...
Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV's Viaskin(r) Peanut in Treatment of Peanut Allergy
July 17, 2014 01:34 ET
|
DBV Technologies
NEW YORK and BAGNEUX, France, July 17, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of food allergies, and...